CSPIA
SRNE

Cary Street Partners Investment Advisory’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-750
Closed -$665 – 1738
2022
Q4 		$665 Buy
+750
New +$995 ﹤0.01% 1604

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Cary Street Partners Investment Advisory's SRNE Position: Q1 2023 in Review

Cary Street Partners Investment Advisory sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 750 shares — an estimated $665 sold.

Cary Street Partners Investment Advisory first reported a position in SRNE in Q4 2022 and held it in 1 quarter. The position peaked at $665 in Q4 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Cary Street Partners Investment Advisory reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 750 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $665.
  • Cary Street Partners Investment Advisory first reported a position in Sorrento Therapeutics, Inc. in Q4 2022 and held it in 1 quarter.
  • Cary Street Partners Investment Advisory's Sorrento Therapeutics, Inc. position peaked at $665 in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q1 2023, filed 12 May 2023.